Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
about
Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.Cisplatin ototoxicity and protection: clinical and experimental studiesHuman OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.Pharmacogenomics in Pediatric Patients: Towards Personalized MedicineCo-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice.Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study.Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.Testicular cancer survivorship: research strategies and recommendations.Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossIncidence of platinum-induced ototoxicity in pediatric patients in Quebec.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsPharmacogenomics of cisplatin-induced ototoxicityImpact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.Canertinib induces ototoxicity in three preclinical models.Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenSOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaChemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF).Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.Genetic variants associated with cisplatin-induced ototoxicity.The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.Pharmacogenomics and active surveillance for serious adverse drug reactions in children.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Complications associated with chemotherapy in testicular cancer management.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Minimizing toxicity in early-stage testicular cancer treatment.Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.Drug-induced oxidative stress and toxicity.Review: ototoxic characteristics of platinum antitumor drugs.Cancer pharmacogenomics in children: research initiatives and progress to date.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?New treatment options for hearing loss.
P2860
Q24615296-DFF7CB59-3C2E-4CE3-90F9-2D1058B93045Q24628775-B19F1E59-63CA-4422-B880-113906BB2722Q27335267-088CEBF3-166E-48CA-B5D9-051C412CBBA7Q28071448-5D343490-3F47-43F1-8660-7C1501F4D724Q28391411-0ED65940-4106-46E7-85BF-5FE27E9D688EQ30447637-2AEDA090-B85C-483A-8FCE-AA0F7AB099F7Q30544354-54DAB25F-EBFE-423C-81FE-33365F625901Q33386412-9A974AC3-C032-4E14-BAF3-03EBE923D0A7Q33523653-EDB9551E-87B1-4409-A9AB-DE08C0BA19A9Q33816134-A48D6952-43CC-43E4-8A02-D2B918FF4A87Q34039684-F82482AE-7CEF-49C6-88F1-B650FCAA93E1Q34682560-C525C469-4A33-4623-864A-9584B6545A84Q35172741-FABC195A-D8C3-4388-85F4-72FE960D9B4FQ35197338-3DC07DDB-9024-4353-9CB3-CE5EA2D132B3Q35327266-BD98378A-FE4B-4C64-935F-EB68A84F65EBQ35553827-F452CD75-4C80-4B36-8709-30E5DBA02B45Q35721076-20FC757F-6E2D-4DF8-9543-0E22924B0505Q36057728-5B061392-51BB-4626-98C3-EB662C9606D8Q36088986-01DA8196-67DC-40B9-8D11-975AB46FFC7AQ36114760-7E90470B-E7BD-4BC6-BF03-8D6D2A092C23Q36322918-44F27B80-391C-426B-8474-1321173362C8Q36358551-F2F76D25-2857-45A6-BE7C-C07B93C38802Q36463837-A93755C6-F48B-4CBF-B4AF-4288582D9CF2Q36546317-8FD6FA43-E4A0-4D71-98F2-DDC7AE4B27A7Q37209628-1D8CA18E-C95F-4EEB-AF1B-7C6601702727Q37284259-5C3B1B24-29F8-434B-9A25-3E06DC8CC45DQ37293994-FD20F1B0-D690-4A68-8BF4-DDEFD48C40A1Q37444522-56C83A48-7174-4E85-A488-867594A72896Q37478015-A98F4F74-8137-4F47-87D4-90A24BC88F3EQ37791154-ECF44E34-9ADE-4D49-8A90-D9B0FD306D0EQ37834445-F5BA8ED0-AC79-4B46-8E1A-51B7A112AC10Q37853021-C082C4C8-530D-4D65-AE65-974BB1E5381CQ37887337-01360F8E-FD02-4D9B-AD66-75EB3EE88D66Q37982443-B9E86929-0172-4E30-A94E-40769ADFA52FQ38003177-AD84D95F-3A90-41D9-A390-30D8112E54E2Q38037517-A1AC0C1F-1358-4536-BC86-989E6D055D7EQ38050374-1ED8CA1E-95F9-4B9D-8EBD-9384B5344832Q38093137-AC93931F-3E0E-4D2C-B983-8F1D157AAE62Q38276429-40E8C51E-18A4-41EF-B9A1-4DF92282B2A7Q38384722-201AD345-08FF-420C-9E67-B712CE357020
P2860
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@en
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@nl
type
label
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@en
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@nl
prefLabel
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@en
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@nl
P2093
P356
P1476
Cisplatin-induced long-term he ...... n testicular cancer survivors.
@en
P2093
Jan Oldenburg
Milada Cvancarova
Sigrid M Kraggerud
P304
P356
10.1200/JCO.2006.08.9599
P407
P577
2007-01-16T00:00:00Z